MaxWell Biosystems
Basel
About MaxWell Biosystems
MaxWell Biosystems provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. Its product MaxOne, electrophysiology platform for recording and stimulating electrogenic cells in vitro. It is a CMOS-based high-density microelectrode array with 26,400 electrodes, 1024 low-noise readout channels, and 32 stimulation channels. It allows extracting single cell and network parameters that facilitate phenotypic screening and drug toxicity/efficacy testing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.7M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Dec 2021)
- Website: mxwbio.com
- Phone: +41 61 551 10 70
Industries & Categories
Biotechnology, Health Care, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/maxwell-biosystems-13632 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.